Dawn R Cochrane

List of Publications by Year
in descending order

23 papers	1,135 citations	567281 15 h-index	610901 24 g-index
24 all docs	24 docs citations	24 times ranked	2674 citing authors

#	Article	IF	Citations
1	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. Human Pathology, 2021, 108, 1-11.	2.0	8
2	Adult‐type granulosa cell tumor of the ovary: a <scp><i>FOXL2</i></scp>‐centric disease. Journal of Pathology: Clinical Research, 2021, 7, 243-252.	3.0	27
3	Modelling hereditary diffuse gastric cancer initiation using transgenic mouse‐derived gastric organoids and single‐cell sequencing. Journal of Pathology, 2021, 254, 254-264.	4.5	11
4	<scp>STING</scp> pathway expression in low‐grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. Journal of Pathology: Clinical Research, 2021, 7, 548-555.	3.0	6
5	FOXL2 in adult‐type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?. Journal of Pathology, 2021, 255, 225-231.	4.5	10
6	Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. International Journal of Gynecological Pathology, 2020, 39, 344-353.	1.4	14
7	Napsin-A and AMACR are Superior to HNF-1β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 593-601.	1.2	20
8	c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract. American Journal of Surgical Pathology, 2020, 44, 495-502.	3.7	16
9	Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. Journal of Pathology, 2020, 252, 201-214.	4.5	31
10	Proteomic analysis of transitional cell carcinoma‐like variant of tubo-ovarian high-grade serous carcinoma. Human Pathology, 2020, 101, 40-52.	2.0	4
11	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase‐Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Clinical Cancer Research, 2020, 26, 4402-4413.	7.0	21
12	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. Human Pathology, 2019, 92, 39-47.	2.0	9
13	Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. Journal of Pathology, 2019, 249, 319-331.	4.5	36
14	The long non‐coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2‐mediated alternative splicing. Molecular Carcinogenesis, 2019, 58, 196-205.	2.7	91
15	TERT promoter mutation in adult granulosa cell tumor of the ovary. Modern Pathology, 2018, 31, 1107-1115.	5.5	49
16	Clear cell carcinomas of the ovary and kidney: clarity through genomics. Journal of Pathology, 2018, 244, 550-564.	4.5	41
17	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22.	28.9	261
18	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nature Genetics, 2017, 49, 856-865.	21.4	220

#	Article	IF	Citations
19	APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecologic Oncology, 2017, 147, 663-671.	1.4	29
20	LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. Gynecologic Oncology, 2017, 147, 642-647.	1.4	13
21	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. Journal of Pathology, 2017, 243, 26-36.	4.5	69
22	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget, 2017, 8, 18949-18967.	1.8	47
23	Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research. Scientific Reports, 2016, 6, 34949.	3.3	100